

Sri Lanka

Support for Vaccine: Inactivated Polio Vaccine This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Sri Lanka																					
2. Vaccine grant number:	15-LKA-08h-Y, 1518-LKA-25b-X, 19-LKA-25b-X, 20-LKA-25b-X																					
3. Date of Decision Letter:	30 September 2019																					
4. Date of the Partnership Framework Agreement:	3 April 2014																					
5. Programme title:	New Vaccine Support (NVS), Fractional Inactivated Polio Virus, Routine																					
6. Vaccine type:	Fractional Inactivated Polio Virus																					
7. Requested product presentation and formulation of vaccine:	Fractional Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID																					
8. Programme Duration:¹	2015-2020																					
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement)																					
	2015-2019	2020	2021	2022	2023	2024	Total ²															
Programme Budget (US\$)	2,442,151	246,000	-	-	-	-	2,688,151															
10. Vaccine introduction grant	Not applicable																					
	<table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th colspan="3" style="text-align: center;">Approval</th> </tr> <tr> <th style="text-align: center;">Year</th> <th style="text-align: center;">Grant Number</th> <th style="text-align: center;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">2015</td> <td style="text-align: center;">15-LKA-08h-Y</td> <td style="text-align: center;">297,000</td> </tr> </tbody> </table> <table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse;"> <thead> <tr> <th colspan="2" style="text-align: center;">Disbursement</th> </tr> <tr> <th style="text-align: center;">Disbursement date</th> <th style="text-align: center;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">25 July, 2014</td> <td style="text-align: center;">297,000</td> </tr> </tbody> </table>							Approval			Year	Grant Number	Amount (US\$)	2015	15-LKA-08h-Y	297,000	Disbursement		Disbursement date	Amount (US\$)	25 July, 2014	297,000
Approval																						
Year	Grant Number	Amount (US\$)																				
2015	15-LKA-08h-Y	297,000																				
Disbursement																						
Disbursement date	Amount (US\$)																					
25 July, 2014	297,000																					
11. Product switch grant	Not applicable																					
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement)																					

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Type of supplies to be purchased with Gavi funds	n/a	2020	2021						
Number of vaccine doses		90,500	-						
Annual Amounts (US\$)	2,442,151	246,000	-						
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.								
14. Self-procurement:	Not applicable								
15. Co-financing obligations:	Not applicable								
16. Operational support for campaigns:	Not applicable								
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> 31 March 2020 15 May 2020 N/A </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>				Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020 N/A	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates								
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020 N/A								
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat								
18. Financial clarifications:	Country shall provide the following clarifications to Gavi*: Not applicable * Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.								

19. Other conditions:

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

Signed by,

On behalf of Gavi



Thabani Maphosa
Managing Director, Country Programmes
30 September 2019